BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 33080996)

  • 1. Synthesis, In Silico and In Vitro Assessment of New Quinazolinones as Anticancer Agents via Potential AKT Inhibition.
    Noser AA; El-Naggar M; Donia T; Abdelmonsef AH
    Molecules; 2020 Oct; 25(20):. PubMed ID: 33080996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, and molecular docking studies of 2-(furan-2-yl)quinazolin-4-one derivatives as potential antiproliferative agents.
    Ahmed MF; Belal A
    Arch Pharm (Weinheim); 2015 Jul; 348(7):487-97. PubMed ID: 25921702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and synthesis of novel quinazolinone-1,2,3-triazole hybrids as new anti-diabetic agents: In vitro α-glucosidase inhibition, kinetic, and docking study.
    Saeedi M; Mohammadi-Khanaposhtani M; Pourrabia P; Razzaghi N; Ghadimi R; Imanparast S; Faramarzi MA; Bandarian F; Esfahani EN; Safavi M; Rastegar H; Larijani B; Mahdavi M; Akbarzadeh T
    Bioorg Chem; 2019 Mar; 83():161-169. PubMed ID: 30366316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pyridazino[1,6-b]quinazolinones as new anticancer scaffold: Synthesis, DNA intercalation, topoisomerase I inhibition and antitumor evaluation in vitro and in vivo.
    Huang WY; Zhang XR; Lyu L; Wang SQ; Zhang XT
    Bioorg Chem; 2020 Jun; 99():103814. PubMed ID: 32278208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and biological evaluation of a novel series of 6,8-dibromo-4(3H)quinazolinone derivatives as anticancer agents.
    Ahmed MF; Youns M
    Arch Pharm (Weinheim); 2013 Aug; 346(8):610-7. PubMed ID: 23873839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and assessment of new series of quinazolinone derivatives as EGFR inhibitors along with their cytotoxic evaluation against MCF7 and A549 cancer cell lines.
    Aziz MW; Kamal AM; Mohamed KO; Elgendy AA
    Bioorg Med Chem Lett; 2021 Jun; 41():127987. PubMed ID: 33771586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quinazoline Based HSP90 Inhibitors: Synthesis, Modeling Study and ADME Calculations Towards Breast Cancer Targeting.
    El-Shafey HW; Gomaa RM; El-Messery SM; Goda FE
    Bioorg Med Chem Lett; 2020 Aug; 30(15):127281. PubMed ID: 32527460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel sulphonamide-bearing methoxyquinazolinone derivatives as anticancer and apoptosis inducers: synthesis, biological evaluation and
    Alqahtani AS; Ghorab MM; Nasr FA; Ahmed MZ; Al-Mishari AA; Attia SM
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):86-99. PubMed ID: 34894963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticancer and DNA binding studies of potential amino acids based quinazolinone analogs: Synthesis, SAR and molecular docking.
    Rakesh KP; Kumara HK; Manukumar HM; Channe Gowda D
    Bioorg Chem; 2019 Jun; 87():252-264. PubMed ID: 30908968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, characterization, enzymatic inhibition evaluations, and docking study of novel quinazolinone derivatives.
    Pedrood K; Sherafati M; Mohammadi-Khanaposhtani M; Asgari MS; Hosseini S; Rastegar H; Larijani B; Mahdavi M; Taslimi P; Erden Y; Günay S; Gulçin İ
    Int J Biol Macromol; 2021 Feb; 170():1-12. PubMed ID: 33352155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and synthesis of quinazolinone tagged acridones as cytotoxic agents and their effects on EGFR tyrosine kinase.
    Babu YR; Bhagavanraju M; Reddy GD; Peters GJ; Prasad VV
    Arch Pharm (Weinheim); 2014 Sep; 347(9):624-34. PubMed ID: 24866341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, Synthesis and Biological Evaluation of Novel N-hydroxyheptanamides Incorporating 6-hydroxy-2-methylquinazolin-4(3H)-ones as Histone Deacetylase Inhibitors and Cytotoxic Agents.
    Minh NV; Thanh NT; Lien HT; Anh DTP; Cuong HD; Nam NH; Hai PT; Minh-Ngoc L; Le-Thi-Thu H; Chinh LV; Vu TK
    Anticancer Agents Med Chem; 2019; 19(12):1543-1557. PubMed ID: 31267876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, and biological evaluation of novel 6-(pyridin-3-yl) quinazolin-4(3H)-one derivatives as potential anticancer agents via PI3K inhibition.
    Yang H; Li Q; Su M; Luo F; Liu Y; Wang D; Fan Y
    Bioorg Med Chem; 2021 Sep; 46():116346. PubMed ID: 34403956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
    El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
    Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors.
    Abdullaziz MA; Abdel-Mohsen HT; El Kerdawy AM; Ragab FAF; Ali MM; Abu-Bakr SM; Girgis AS; El Diwani HI
    Eur J Med Chem; 2017 Aug; 136():315-329. PubMed ID: 28505536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of newly synthesised quinazolinone-based CDK2 inhibitors with potent efficacy against melanoma.
    Mohammed ER; Elmasry GF
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):686-700. PubMed ID: 35139719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, green synthesis, molecular docking and anticancer evaluations of diazepam bearing sulfonamide moieties as VEGFR-2 inhibitors.
    Saleh NM; El-Gaby MSA; El-Adl K; Abd El-Sattar NEA
    Bioorg Chem; 2020 Nov; 104():104350. PubMed ID: 33142416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, in silico and in vitro evaluation of thiophene derivatives: A potent tyrosine phosphatase 1B inhibitor and anticancer activity.
    Gulipalli KC; Bodige S; Ravula P; Endoori S; Vanaja GR; Suresh Babu G; Narendra Sharath Chandra JN; Seelam N
    Bioorg Med Chem Lett; 2017 Aug; 27(15):3558-3564. PubMed ID: 28579122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis, molecular docking, and anticancer activity of benzoxazole derivatives as VEGFR-2 inhibitors.
    El-Helby AA; Sakr H; Eissa IH; Abulkhair H; Al-Karmalawy AA; El-Adl K
    Arch Pharm (Weinheim); 2019 Oct; 352(10):e1900113. PubMed ID: 31448458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis, Antiproliferative, and Antioxidant Evaluation of 2-Pentylquinazolin-4(3
    El-Sayed AA; Ismail MF; Amr AEE; Naglah AM
    Molecules; 2019 Oct; 24(20):. PubMed ID: 31640238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.